Lexapro and Bone lesion - a phase IV clinical study of FDA data

Summary:

Bone lesion is reported as a side effect among people who take Lexapro (escitalopram oxalate), especially for people who are female, 50-59 old, also take Zometa, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Bone lesion when taking Lexapro. It is created by eHealthMe based on reports of 82,231 people who have side effects when taking Lexapro from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,465 Lexapro users. Check the latest studies of Lexapro.

What is Bone lesion?

Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries) is found to be associated with 854 drugs and 501 conditions by eHealthMe. Check the latest studies of Bone lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

82,231 people reported to have side effects when taking Lexapro.
Among them, 210 people (0.26%) have Bone lesion.

Among these 210 people:

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and have Bone lesion?

- Check whether Bone lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lexapro:

Lexapro (91,465 reports)

Bone lesion treatments and more:

Bone lesion (6,686 reports)

How severe was Bone lesion and when was it recovered:

Bone lesion in Lexapro

Expand to all the drugs that have ingredients of escitalopram oxalate:

Bone lesion and drugs with ingredients of escitalopram oxalate (233 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lexapro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone lesion:

Bone lesion (854 drugs)

Browse all the conditions that are associated with Bone lesion:

Bone lesion (501 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Lexapro) and Lexapro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.